Research progresses of cytochrome P450 reductase

Chinese Pharmacological Bulletin

Volumn 22, Issue 2, 2006, Pages 129-133

  Cheng, Jie ^a,b   Yang, Ling ^a  

^a Laboratory of Pharmaceutical Resource Discovery   (China)

^b Graduate School of Chemical Academy of Science   (China)

Author keywords

Cytochrome P450 reductase; Cytochrome P450s; Electron transfer; Gene modulation; Substrate function

Indexed keywords

CYTOCHROME P450 REDUCTASE; MEMBRANE PROTEIN;

ARTICLE; DRUG METABOLISM; ELECTRON TRANSPORT; GENE CONTROL; GENE EXPRESSION; RESEARCH;

EID: 33646266260     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Masimircmbwa CM, Otter C, Berg M et al., Heterologous expression and kinetic characterization of human cytochromes P450: validation of a pharmaceutical tool for drug metabolism research[J]. Drug Metab Dispos, 1999, 27(10): 1117-22.
2. Wang M, Roberts DL, Paschke R et al. Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes[J]. Proc Natl Acad Sci U S A, 1997, 94(16): p8411-6.
3. Shen AL et al. Structural analysis of the FMN binding domain of NADPH-cytochrome P-450 oxidoreductase by site-directed mutagenesis[J]. J Biol Chem, 1989, 264(13): 7584-9.
4. Paine MJ et al. Role of the conserved phenylalanine 181 of NADPH-cytochrome P450 oxidoreductase in FMN binding and catalytic activity[J]. Biochemistry, 2001, 40(45): p13439-47.
5. Shen AL, Kasper CB. Differential contributions of NADPH-cytochrome P450 oxidoreductase FAD binding site residues to flavin binding and catalysis[J]. J Biol Chem, 2000, 275(52): 41087-91.
6. Shen AL, Sem DS, Kasper CB. Mechanistic studies on the reductive half-reaction of NADPH-cytochrome P450 oxidoreductase[J]. J Biol Chem, 1999, 274(9): 5391-8.
7. Hubbard PA, Liang X, Schulz H, Kim J. NADPH-cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer[J]. J Biol Chem, 2001, 276(31): 29163-70.
8. Gutierrez A, Lian LY, Wolf CR et al. Stopped-flow kinetic studies of flavin reduction in human cytochrome P450 reductase and its component domains[J]. Biochemistry, 2001, 40(7): 1964-75.
9. Murataliev MB, Feyereisen R. Mechanism of cytochrome P450 reductase from the house fly: evidence for an FMN semiquinone as electron donor[J]. FEBS Lett, 1999, 453(1-2): 201-4.
10. Murataliev MB, Feyereisen R. Interaction of NADP(H) with oxidized and reduced P450 reductase during catalysis. Studies with nucleotide analogues[J]. Biochemistry, 2000, 39(17): 5066-74.
11. Shen AL, Kasper CB. Role of acidic residues in the interaction of NADPH-cytochrome P450 oxidoreductase with cytochrome P450 and cytochrome C[J]. J Biol Chem, 1995, 270(46): 27475-80.
12. Backes WL, Kelley RW. Organization of multiple cytochrome P450s with NADPH-cytochrome P450 reductase in membranes[J]. Pharmacol Ther, 2003, 98(2): p221-33.
13. Eyer CS, Backes WL. Relationship between the rate of reductase-cytochrome P450 complex formation and the rate of first electron transfer[J]. Arch Biochem Biophys, 1992, 293(2): 231-40.
14. Curk T, Strobel HW. Role of LYS271 and LYS279 residues in the interaction of cytochrome P4501 A1 with NADPH-cytochrome P450 reductase[J]. Arch Biochem Biophys, 2001, 385(2): 290-300.
15. Marohnic CC, Barber MJ. Arginine 91 is not essential for flavin incorporation in hepatic cytochrome b(5) reductase[J]. Arch Biochem Biophys, 2001, 389(2): 223-33.
16. Crespi CL, Miller VP. The use of heterologously expressed drug metabolizing enzymes-state of the art and prospects for the future[J]. Pharmacol Ther, 1999, 84: 121-31.
17. Guengerich FP, Parikh A, Johnson EF et al. Heterologous expression of human drug-metabolizing enzymes[J]. Drug Metab Dispos, 1997, 25(11): 1234-41.
18. Hummel W. Large-scale applications of NAD(P)-dependent oxidoreductases: recent developments[J]. Tibtech, 1999, 17: 487-92.
19. Gilep AA, Guryev DL, Usanov SA, Estabrook RW. Expression, purification, and physical properties of recombinant flavocytochrome fusion proteins containing rat cytochrome b(5) linked to NADPH-cytochrome P450 reductase by different membrane-binding segments[J]. Arch Biochem Biophys, 2001, 390(2): 222-34.
20. Sem DS, Kasper CB. Effect of ionic strength on the kinetic mechanism and relative rate limitation of steps in the model NADPH-cytochrome P450 oxidoreductase reaction with cytochrome C[J]. Biochemistry, 1995, 34(39): 12768-74.
21. Shackleton C, Marcos J, Arlt W, Hauffa BP. Prenatal diagnosis of P450 oxidoreductase deficiency (ORD): a disorder causing low pregnancy estriol, maternal and fetal virilization, and the Antley-Bixler Syndrome phenotype [J]. American of Medical Genetics, 2004, 129: 105-12.
22. Bartoszek A. Metabolic activation of adriamycin by NADPH-cytochrome P450 reductase; overview of its biological and biochemical effects[J]. Acta Biochim Pol, 2002, 49(2): 323-31.
23. Kuznetsov VY, Ivanov YD, Archakov AI. Atomic force microscopy revelation of molecular complexes in the multiprotein cytochrome P450 2B4-containing system[J]. Proteomics, 2004, 4(8): 2390-6.
24. Gutierrez A, Paine M, Wolf CR et al. Relaxation kinetics of cytochrome P450 reductase: internal electron transfer is limited by conformational change and regulated by coenzyme binding[J]. Biochemistry, 2002, 41(14): p4626-37.
25. Simmons, DL, Quiddy PM, Kasper CB. Induction of the hepatic mixed-function oxidase system by synthetic glucocorticoids. Transcriptional and post-transcriptional regulation[J]. J Biol Chem, 1987, 262(1): 326-32.